GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (LTS:0S54) » Definitions » Debt-to-Revenue

Arena Pharmaceuticals (LTS:0S54) Debt-to-Revenue : 190.79 (As of Dec. 2021)


View and export this data going back to 2018. Start your Free Trial

What is Arena Pharmaceuticals Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Arena Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $5.05 Mil. Arena Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2021 was $36.16 Mil. Arena Pharmaceuticals's annualized Revenue for the quarter that ended in Dec. 2021 was $0.22 Mil. Arena Pharmaceuticals's annualized Debt-to-Revenue for the quarter that ended in Dec. 2021 was 190.79.


Arena Pharmaceuticals Debt-to-Revenue Historical Data

The historical data trend for Arena Pharmaceuticals's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals Debt-to-Revenue Chart

Arena Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.89 2.93 0.06 142.98 763.17

Arena Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 308.19 N/A N/A N/A 190.79

Competitive Comparison of Arena Pharmaceuticals's Debt-to-Revenue

For the Biotechnology subindustry, Arena Pharmaceuticals's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arena Pharmaceuticals's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arena Pharmaceuticals's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Arena Pharmaceuticals's Debt-to-Revenue falls into.



Arena Pharmaceuticals Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Arena Pharmaceuticals's Debt-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(5.052 + 36.159) / 0.054
=763.17

Arena Pharmaceuticals's annualized Debt-to-Revenue for the quarter that ended in Dec. 2021 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(5.052 + 36.159) / 0.216
=190.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2021) Revenue data.


Arena Pharmaceuticals Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Arena Pharmaceuticals (LTS:0S54) Business Description

Traded in Other Exchanges
N/A
Address
136 Heber Avenue, Suite 204, Park City, UT, USA, 84060
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Arena Pharmaceuticals (LTS:0S54) Headlines

No Headlines